Estela Rodriguez: LCRP not only helps find the cures of tomorrow but also invest in stem careers
Estela Rodriguez, Assistant Director of Diversity, Equity and Inclusion at Sylvester Comprehensive Cancer Center, shared Jill Feldman’s, Co-Founder of EGFR Resisters, post on X:
“Feeling the pain and frustration of cancer researchers and patient advocates that are seeing already underfunded lung cancer research programs like Department of Defense, CDMRP LCRF cut. These program do not only help us find the cures of tomorrow but also invest in stem careers.
Jill Feldman‘s post on X:
“As a member of the programmatic committee for the Department of Defense CDMRP Lung Cancer Research Program (LCRP), I’m not surprised that LCRP isn’t included in the list of funded programs for 2025. Still, it is truly devastating to our community.
Historically, lung cancer has faced disparities in federal research funding. Despite being the 1 cancer -accounting for 20-25% of all cancer deaths, it only receives 5-9% of federal funding. I remember how hard our community fought to get LCRP included back in 2009. It was a huge milestone that gave our community Hope.
Consistent funding is essential. Cuts or interruptions in funding delay progress and impact innovation (especially early-stage, high-risk/high-reward projects that require seed funding). It quite literally threatens lives. The impact is profound, and we will feel/see the effect for decades to come.
Deep gratitude to the advocacy organizations and individuals who continue to stand up and speak up. We see you. We thank you. We won’t stop!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023